Resolvyx Gains Chronic Dry Eye Therapy Patent

The US Patent and Trademark Office has granted a patent to Resolvyx Pharmaceuticals for its chronic dry eye syndrome treatment, RX-10045.

RX-10045 has been formulated as a topical eye drop that was recently evaluated in a phase 2 clinical study showing positive results for the treatment of patients with chronic dry eye syndrome, the company reported.

Resolvyx claims that in addition to this patent, company has an issued patent in Europe and a pending patent application in the US for RX-10001, an orally available Resolvin therapeutic currently in phase 1 testing with potential to treat inflammatory bowel disease, asthma and other inflammatory diseases.

Greg Weinhoff, executive chairman of Resolvyx, said: “Just last month, we reported positive results from a 232-patient phase II trial in which RX-10045 improved both signs and symptoms of chronic dry eye. We are very pleased to have the first US patent covering this class of compounds that has the potential to be an important therapy for chronic dry eye syndrome and other ophthalmic diseases.”